WO2024047580 - ENFORCED TISSUE RESIDENCY OF PAYLOAD MOLECULES BY ACOUSTIC DISRUPTION
National phase entry is expected:
Publication Number
WO/2024/047580
Publication Date
07.03.2024
International Application No.
PCT/IB2023/058628
International Filing Date
31.08.2023
Title **
[English]
ENFORCED TISSUE RESIDENCY OF PAYLOAD MOLECULES BY ACOUSTIC DISRUPTION
[French]
RÉSIDENCE TISSULAIRE FORCÉE DE MOLÉCULES DE CHARGE UTILE PAR RUPTURE ACOUSTIQUE
Applicants **
INSIGHTEC LTD.
P.O. Box 2059
39120 Tirat Carmel, IL
Inventors
ZADICARIO, Eyal
c/o Insightec Ltd.
P.O. Box 2059
3912001 Tirat Carmel, IL
LEVY, Yoav
P.O. Box 2059
39120 Tirat Carmel, IL
PLAKSIN, Michael
c/o Insightec Ltd.
P.O. Box 2059
Tirat Carmel, IL
BERCOVICI, Tiran
c/o Insightec Ltd.
P.O. Box 2059
3912001 Tirat Carmel, IL
TOLTSIS, Gabriella
c/o Insightec Ltd.
P.O. Box 2059
3912001 Tirat Carmel, IL
Priority Data
63/402,493
31.08.2022
US
63/453,924
22.03.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1323 | |
| EPO | Filing, Examination | 6957 | |
| Japan | Filing | 531 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 3035 |
Total: 12453 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
A system (100) for controlling drug delivery through a tissue barrier includes an ultrasound transducer (104) and a controller (108). The ultrasound transducer is for sonicating a target volume to cause disruption of the tissue barrier and thereby increase a permeability thereof. The controller is configured to receive a specification of a target molecule, where the specification includes a pharmacokinetic parameter of the target molecule or a molecular size of the target molecule. The controller is also configured to operate the ultrasound transducer in accordance with the specification to permit passage of the target molecule through the tissue barrier in a manner that traps a target fraction of the target molecule behind the tissue barrier for a predetermined time period.[French]
Un système (100) pour commander l'administration de médicament à travers une barrière tissulaire comprend un transducteur ultrasonore (104) et un dispositif de commande (108). Le transducteur ultrasonore est destiné à ultrasoniquer un volume cible pour provoquer une rupture de la barrière tissulaire et ainsi augmenter sa perméabilité. Le dispositif de commande est conçu pour recevoir une spécification d'une molécule cible, la spécification comprenant un paramètre pharmacocinétique de la molécule cible ou une taille moléculaire de la molécule cible. Le dispositif de commande est également conçu pour faire fonctionner le transducteur ultrasonore en fonction de la spécification pour permettre le passage de la molécule cible à travers la barrière tissulaire d'une manière à piéger une fraction cible de la molécule cible derrière la barrière tissulaire pendant une période de temps prédéterminée.